FLINT, MI - Dr. Bobby Mukkamala, a prominent Flint-based physician, was speaking at a medical conference last month when his ...

Glioblastoma survival has not improved in the last 30 years and there is an urgent need to develop novel therapeutic approaches for it.

Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Immunotherapy has changed the way physicians treat patients and has improved standard of care for many different tumors. Unfortunately, solid tumors are st | Immunology ...

Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished ...

This discovery is important because until now, we have not had compelling evidence that temozolomide improves overall survival in grade 2 gliomas," said lead investigator David Schiff, MD ...

After a phase 3 clinical trial showed efficacy in prolonging imaging-based progression-free survival in patients with residual or recurrent low-grade glioma who had not received treatment (except ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

The Wistar Institute’s David B. Weiner, Ph.D., and his laboratory created a new therapeutic design for glioblastoma, the deadliest form of brain cancer. The lab engineered molecules called ...

a novel monoclonal antibody (mAb) candidate that inhibits the NOTCH signaling pathway and is being developed for the treatment of high-grade gliomas (HGGs).